0001193125-24-090983.txt : 20240409 0001193125-24-090983.hdr.sgml : 20240409 20240409172902 ACCESSION NUMBER: 0001193125-24-090983 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240404 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 24833666 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 d814314d8k.htm 8-K 8-K
Adaptive Biotechnologies Corp false 0001478320 0001478320 2024-04-04 2024-04-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: April 9, 2024 Date of earliest event reported: April 4, 2024

 

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Washington   001-38957   27-0907024

(State or Other Jurisdiction

of Incorporation)

   (Commission
File Number)		  

(IRS Employer

Identification No.)

 

1165 Eastlake Avenue East

Seattle, Washington

     98109
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.0001 per share   ADPT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, Adaptive Biotechnologies Corporation (the “Company”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.

In connection with his appointment as Chief Financial Officer, Mr. Piskel has entered into an executive employment agreement with the Company that provides for an annual salary of $380,000 per year and an annual target bonus of 40% of eligible earnings conditioned upon completion of performance goals. Mr. Piskel will also receive a restricted stock unit grant of 31,260 shares (the “RSU Grant”) and a performance stock unit grant of 75,000 shares (the “PSU Grant”). The RSU Grant and the PSU Grant are in addition to the annual equity refresh of 43,740 restricted stock units Mr. Piskel is entitled to. The RSU Grant vests 25% on each of the first four anniversaries of the vesting commencement date and the PSU Grant is subject to a three year performance period. Mr. Piskel will receive the severance benefits provided to Executive Vice Presidents under the Company’s form of Executive Severance Agreement as described in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 28, 2023, and he may also participate in other standard Company benefit programs.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

10.1    Executive Employment Agreement between the Company and Kyle Piskel dated April 4, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    Adaptive Biotechnologies Corporation
Date: April 9, 2024     By:  

/s/ Chad Robins

      Chad Robins
      Chief Executive Officer
 EX-10.1 2 d814314dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

LOGO    LOGO

April 1, 2024

KYLE PISKEL

 

Re:

Promotion

Dear Kyle:

Congratulations on your promotion to the position of Chief Financial Officer. You will report to Chad Robins, Chief Executive Officer in your new role. This letter sets out the terms of your new “at will” position with Adaptive, which will become effective on April 8, 2024.

Compensation

Your new full-time position is Exempt and you will be paid a base salary of $380,000 per year, less applicable tax and other withholdings.

Benefits

You will not experience a change in your benefits and will continue to be eligible to participate in the various health and welfare benefit plans, including group health insurance and vacation programs as selected and enrolled.

Bonus

For 2024, your target bonus is 40% of your eligible earnings. Your participation is conditioned upon your continued employment with Adaptive through the payment date(s) for the relevant year’s Bonus Plan and will be modified depending on your percentage of completion of performance goals established by you and your manager, Bonus Plan adjustments made by the Compensation Committee and other factors as set forth in the Adaptive Bonus Plan.

Equity Awards

In connection with your new role, you will be issued a restricted stock unit (RSU) grant of 31,260 shares, and a performance stock unit (PSU) grant of 75,000 shares. Combined with the 43,740 RSU’s in your 2024 Annual Equity Refresh, this results in a total of 150,000 combined shares granted this year. The grant date of these awards will be one of Adaptive’s standard grant dates, to be determined based on your promotion effective date. Your RSU grant will vest over a period of four (4) years, with twenty-five percent (25%) of the shares vesting in equal increments on each of the four anniversaries of the vesting commencement date. The performance period for your PSU awards is three (3) years from the grant date, and payout will be subject to the Relative Total Shareholder Return (rTSR) of Adaptive’s stock as compared with an established index of biotech peer stocks, per the terms of your separate PSU Award agreement. 

Vesting for all awards are subject to your continued service through the applicable vesting dates. All equity awards are subject to the terms and conditions of Adaptive’s equity incentive plan and standard forms of equity agreement, both of which you will be required to sign as a condition of receiving the awards.

Your employment with Adaptive remains “at will”; it is for no specified term and may be terminated by you or Adaptive at any time, with or without cause or advance notice. Adaptive may also change your compensation package or responsibilities at any time, with or without cause or advance notice.

[Redacted]

This offer letter, in conjunction with your prior Noncompetition, Nonsolicitation, Proprietary and Confidential Information and Developments Agreement (“Restrictive Covenants Agreement”) and Severance Agreement, together constitute the entire agreement between you and Adaptive regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and Adaptive. For clarity, you are and remain bound by the terms of the Restrictive Covenants Agreement and your employment continues to be subject to the terms of your Severance Agreement. The provisions of this letter regarding “at will” employment may be modified only by a document manually signed by you and Adaptive’s CEO.

Promotion & RCA

April 1, 2024

Page 2

 

Congratulations again on your new role within Adaptive, we are pleased to have you continue your career with us! Please sign and date this letter in the spaces provided below to acknowledge your acceptance of the terms of this letter.

 

Sincerely,

Adaptive Biotechnologies Corporation

By:

  

/s/ Francis Lo

Date: April 4, 2024

Francis Lo

Chief People Officer

I agree to and accept this position change with Adaptive Biotechnologies Corporation on the terms and conditions set forth in this agreement.

 

By:

  

/s/ Kyle Piskel

Date: April 4, 2024

Kyle Piskel

 EX-101.SCH 3 adpt-20240404.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 adpt-20240404_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 adpt-20240404_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g814314page1a.jpg GRAPHIC begin 644 g814314page1a.jpg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end GRAPHIC 7 g814314page1b.jpg GRAPHIC begin 644 g814314page1b.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 04, 2024
Cover [Abstract]  
Entity Registrant Name Adaptive Biotechnologies Corp
Amendment Flag false
Entity Central Index Key 0001478320
Document Type 8-K
Document Period End Date Apr. 04, 2024
Entity Incorporation State Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code (206)
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d814314d8k.htm 7 adpt-20240404.xsd adpt-20240404_lab.xml adpt-20240404_pre.xml d814314d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d814314d8k.htm": { "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20240404", "dts": { "schema": { "local": [ "adpt-20240404.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "adpt-20240404_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20240404_pre.xml" ] }, "inline": { "local": [ "d814314d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-04_to_2024-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d814314d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-04_to_2024-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d814314d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.adaptivebiotech.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-24-090983-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-090983-xbrl.zip M4$L#!!0 ( *"+B5@/N_Q-00, &$+ 1 861P="TR,#(T,#0P-"YX M\Y.TJ7=6LJ&6#_,]=US]]Q/]^CM;2GA&HT56HVC-!E$@"K7A5#S<53;F-M< MB.CM\?-G1R_B&$[/SB\AAH5SEP00EU!PAQF\9NF D>)K2+/A MF^Q@!":L<(:Y986,E&+20B/RJ ?]/>X>A@KA)78%G'$[#:!.XM,SZB%X4;DU-[S@ ME1/7.!7:8;X(A?+9&="GARM0K&"!F<4\F>MK1H)-'UXN'HYE.!B,&/6%HW1C M#R*%^KD#X<53:I&^DWN0FU$ I(>'ARQ(-R@5;CV"UOH!:X1!FSMGQ+1V>*9- M>8HS7DM"U>K_FDLQ$U@$+>K7$I5;TUG7<-S,T5WR$FW%++Z'SHF,/ C-*,I*&P=-3U[H/(S*CJSZ;W%7C-A?Q>DP'J4)&8M /4A^ M2R6!/9E(5^-'$5DUR-Y$[+9&]H?8'[9Y?[C]'YV!S?'V\1_Z^-,W>\5_;SW\ M!29:73Z53&_'/;XFBHN\66'-'.;M%Z#3ZZ4=L%1 MGPFO*J%FNKVB2]_$6=?)$YQ!V&(9-[G1$G?O.E897:%Q@E;^W3 T!A8&9^/( M;_ZXVS,_))\FM&NP3C@/OO!B\')Z.[ER;8_Z<=L.ZZ][>K633/;'.?VIC_VS56S=NCK+U!+ P04 " "@BXE8;O&/)& & M "^0P %0 &%D<'0M,C R-# T,#1?;&%B+GAM;,V<;6_;-A#'WQ?H=[AY M;S:@LF.G&U"C:9$YR1 L3TC<;=@P%++$V,0HTB#EQ/[V(_70R#$E2^%IRHNF MBG3WO_L[OV-HV<['S^N(P0.1B@I^U!OV#WI >"!"RN='O97R?!50V@,5^SST MF>#DJ+#Q\;$?WE.N!%O%6E+U Q$- MP//R^,GT"_R>EAO#+6'$5P0B7\5$PB\KRL+QZ&!T.#P8COJC8IHDOM&#T(_) M&-X/A@<#'?@>AN/1S^.?#N'X$DX3%0Y3&I%BJEAN))TO8O@A^!&2I!/!.6&, M;.",RC6,\GZ0LYUKP>'@SRE]Y2QWDEY/$P2AA\^?!@D5XO1BMIB MM?AP\.?EQ5VP()'OZ4=?_[2"K(RB8Y6<.0= M#OMK%?8^F8+9H^//"+O01Y!X&$O!2$5AJAKU$4I&@/QGP>_W-UXG0N!_/5"S](-ZNQ\Q# M)&1^,C%QU+,D#;8;,G'',MC2\F60Z^C#/?ZSB$$@],]M&7N)8IY^+T5D[2(K M)RP7O[(9L[9I2-)'9KH)][[<[?.:"A6-2:+$2FJ\FOQH$S^?$F7X.]?^Y^/@ MJ?9K:54O(8I<-.W7#@RTF?G>B>Q_HULFBVL.\F=KJQE5D1%D/O: M:A7$75RS$I#4 %T$:7EMI77+^MJ@?S>D3T2P,G,SU=W7)7D[IR. K8V+W6LN MN.[J(%&:"X-1=D83O\TBD35[Q<'PAD@JPE,>GNCGY4UY?);<,9AV*Z(B" -5 MBR VLVD)T#7 %$'#MX76K1S7[A]CLW#. R&70B:W2NYB76\B5GIMWTQ$V/ Y MV1ZI3C<2]6R*VBGNFXP:\KA;CJV"D%2$K"28FD@[D/_!EV4_\G)S&$-T1AFY M6D4S(IM-3#&OT_&P&!#VZ^[@/]?"I=RH0RJ/!#1VOQ9Z:S6- >K47Y^'^G<, MO:?IS?&74%LJTBG"^ZR)&L'N<%<*XY*N2\%V+5SN6[5B&8(7^,$8B>,PU 94 M]M\%Y638;!RL IV.0I4EL2?0?01*17'QS_3?Y0=@*L$UQ]K'M&;#@OX+O""B M/]&'UW(J'OF+P"^FOP;L+79LT#^%H2'_7+(EX$T9$!),(5S8L0U4H5[/!2+F MR9.":WDCQ0/E0-\HXG.+WN?4&J)K- MNH%HWIG(;A:"-[QIN)O7$9"E!H3]N@N8=BTD.!-Q2-2Q;IZTTV\1TB9-NX'Z MAZ1Q3/A$1-&*9S=E5%U:2Y([0K;:BJ@( M#><[P6A 8\KGEWK'+:G/ZK)LR^P(Y H3HBS"!>$R-21^G^0AUW>&MZV6B^0V MZML-VQM)S'P0C47R+AKS$0%Y?7]??^-0I= 1QC5,B7V1+ECO4T7"6Y>!8AU( M"T%2R1GTMDT4@7^A$U3TSY5:$>D^ !:=US$&Y0;MP[ 3CS@2)=IM#49:KM7Y M:,E1Y90TLN6XO2'!2N^G-L/1;$IC5OL>QVY>5UN;,@/"?MUI6V/5PMK49.*@ MU2&1=]_3M-+OUHZF0=-NH$ZE;SYO>[>)9J+V%OQ94D>(VEL7EHLN<%J$D,C, ME"&5=J:RA4:+2-;M%F?=/%T'"^V6-/DTHCVWX_73:D24QV"LH[MZV&MI7@'G MTXCM]6U=4VLVC_'ZWFE$Y%Q/S:]2/,8+O1E9^KSAA\!*)#I]A:_:EM@;ZOX: M7X4L$NO9"V-Y(4@K058*Z36^%FU87N2KZZ5XXD(?F;\[D9VBZ5]?T&?^ U!+ M P04 " "@BXE8!R&>LKP$ "**@ %0 &%D<'0M,C R-# T,#1?<')E M+GAM;-6:;6_J-A3'WU_I?@[-)"R'0WJVH](K1]@JM3Z+<;=J;*Y,7:.?R #D31(CW,RM#*--C6H%T@;FZB(-J:;HMMF.G"C8UBSW1(MV(8DO+BZB MXFBYOF95M;&!./K]_NXYF4%&0V2 S)*=IM!-:OY6;YL[C]8'77W-.KJ(=">3 M(O5'=(L\]D=X(P\QJ("92946' E+D MMC-3,.D&-,U-Z*)96]\.,="74P*958ZGAV99SB$@T5:W;6/.7V&$Q *4COUDDX:+9PBM.KAJ+F5V;6PZ&: MVN%ZR^GT6%@[HOI2VC'J\+2]P;,>9GWL@:)\@'/5\A=8G79.[8GKB^N 88?M MS!ML[AHPPC0>2ZNLJ2^DLD_'YH-W;)X O>(E.KW&A>VID';$]:>U8]AA^]$; M;&XME4B52U7D]AE3#'TYQ^EBU9?IB6N-?PA57Z1'V7> ?_(,\"WC\##/QJ!. MH[FMJSNZ;:^.TX5GG$9T.4@Q#6S"UC>I;X%V,$C="1XTOL'9;GJ&LY>FF&2] M><,;98A/0UD9H.X8*TT[A+&?"/OX\5&-Y$*\">"VW!-\VY8=/']NP$M=*:[C MC^I)R1=F=Q#?0G OAB<8]WP[EK[=K6_Z\R2UH?P/EI^^-*V.X G''=>.HC\W M[W8^Z2F@IW K:^I+JNS3L3GWAHW]280_S:0X\29A7U=?1OM>'2=_-EE^0W\& M1%]FV5QLULCZ6%@'Q/4E=L"PP^;/)LNSY"QAAHGI/5Z,%;/6CF-6I:POL"JW MCI8_.R9/"NR0 UPM%1NR]K=,]3B9'#\MOA:AOO1><^TH^K.?LM.;@=9S4/^> M944<;XA6>-]P/?-G8^49DKFU&+?&(V;XT4O)?5U]N>U[=9S\V3T9*6J?N7I> M96-Y].5N1U1?0CM&'1Y_]D?<$+M9)C,JIG#*0R75VOK"JO;KF/FV#W*3@9KB MV/NDY,+,<'[/J3CQV84#(>I+\%7;#N3_L!5R&>VEY@X+[#.4ZR/VQ3X1B"5_ M 5!+ P04 " "@BXE8!F\>%(,0 K9P #@ &0X,30S,31D.&LN:'1M M[5UM7C[X==ZI]%J_?JWVL'Y0 ,9D(:JZC/^(3/0.JKF\^.>#'**>;E;<9>'@GS! M*10S,>%(9?4D8FI*W:>JEQ/R-I^4S)&'(@Q'PRGQ_?U]SC2/%7PM\U@C#T19 MH&*2>TF]<<##;W/5[HNFDENI5/*F-"%=HIQV4'"<8AZ+>U2QA)SZD9XCISZ- M-+]C/2XT\P8Y3PQQ""4'_INRH_@J9J #-__'U\N.-V!#FN6ATC3TIEV-M%S+ M6"4/I0DA5Z)4<$\?&$5,,:TP7D?K FT(8V9_?&Q?SLCU:OH9:5Y+&JJ^D$.J M 378TG'6*60+)ZE&LH"*N882E&QJIYPMNE-90N?\H:$N2!%+_05TQL0G>5L8 MDZ['"R(]@XAGU(=?FNN U??J0T6RL\Z:Y/-3*VP8)(><]X4]JYSZ_(TI/ O8AXW,5!72"2X!E:N2< MCZM(S63\F?L^"^UG(+FR^"?<_Y#YS13]"4OOSV8(#$[:[)8K%*R^HD/@)H2? MT 'CU=7EAMNQ;K,^4(VDF8D_$=-9!___4XO44Z96CU< ^6B70"@"<A?TJ 5 M^FS\A4V69;5$\$AA.;#F2Z?E8L%9YB^_,*^2]9D$SD,Y7F3'KYM+[(@UZ!7RGM@K6R M-."W8=6#L3"9F2^_Y[X>5,NY8QZ>I6@#UM=G0RIO>9C%SU5"1UHDWTA^.XB_ MPN:BI#%4[MD!,Z7@3433)K2(JJG'GM!:#,TW/2&!]>0;-QH3)0+NDU\<\R=3 M^^LO[HES=IZ/UG54W-Q1X0"D#U.35?R_K.J6I\]].N3!I-KE M0U"/5^R>M,60AF>F[-[RW1.!?[9B>GZ_:G6;%Z33K7>;G?7L."_$3J?9^+W= MZK::'5*_NB#-/QJ_U:\^-TGC^NO75J?3NK[:B4!L6E$KD7GR)&3F'"";!^>97:4%]]WRZ+=LS*/I$#QCR M-I)''L#&MXR4OD(69^=;.JN#$.4]/Z48_6&38.1;VAJSXT,(3J Y].)L 0 M"],Z!<,@PWK)LOZF75Y"NQ1*^\ @.5<1#1,.".Y29/DX:R.QZJ9HNE:_J-]T M6_]HDH^MZVZS\=O5]>7U9_2+&M=M4%?UKO&%L OTQ'?0#,X^!GO8'%/0 +A2 M[+I+!D.H(IV(>1CH^(2'I*4A@A] L,+DHD9[@^\:^.XBF(-S37L!(QX+ D"+ MA[NM&2=CGB/J^\ESW%4\5$\$ 8T4JR8?'H9("D_HL%EAN([S+A9=U8FYK#I) M' =\2?/3GP\.BZ5W&,>G"^Z8U-RC02Q5.]!%HKAV8;O:"8M+U.EFSO,QBS(I MC>@MR_8DH]]P6Q4B^"J]$X""K:7CFNF9ZY&D $/F$%,U6"$+ X!IS]3F=,OB M H7B=0;,ZII6Z D)QLX8JHX&$]00HU#+24/X.YDS5'*X%:%9),4==CMOSXXA M>J)J )C3(EPV9D:;@=3];>9_"O)%\E<0Z"<>,"CK@:IY>@!Q@KM$;K98KAR? M_D2RZ=)Q*][J\HPP=A;4::96.,TZ%>=TI4LTD]0S+.#R?M;O4ZWU7L+A0[/D M,:ZX!G=>DK^#-Z]\;@*.1[D2[C,P!][#G'IZ;RWB=XC[PX88#KG"=.9Y3^9K MJ 2(!??[5UVOKPNN5KM#FL,H$!,F7QU-\YJ'7(G<#$]&.\ /=(]^5&_+>.]O M[M8SNEO)"GW=^&J#C:W[OF1*Q;\N(<)Q=["OY4S-=4^.29,J'=!OC-3O6#AB MYGG##L2C5OA+BJ8!'Z]E5]R'.PBFDJEU&-4Z6,H"'ZW?,YICPUC>:WD#WC$W MIPF>S=$E[N_FH\>S<")!G\"\>/2D.FHG>S=0J9=>I M_)B^Z2:W)Q86[O/<2$ QCVA FF/FCL^F%NF]N8"K6#Q92&VE5 - 11 M\WYICE=X&(_<$M^+FIQMR?WUEW+!/3U3I,L"%@U$F'BM1^AY!R-T4D@=<&@& M],!N..I4I-MQM11 ? 7GY/WV9WHN!5K..\93[I MH'DCE^ QQ$F8M\W>Y\F$;L)9IM88,.^;2=S1"%R%2'*,_GMB3'HL$/6H@MM= :QI=S2*NY=!N M(?3;RL9G5D5%I7=G*RW1.JWX3\DUS!?N2HS"..)5.WN8/2&"'H6YTH"8M.8L MH;PKIZ72V;+BW,*&I^>9S$\MV5FW+IPM T_8R@:$D18.B5(9]_8(X%(J',=0 M74AT8W[[T#TEC4]M4B@Z.2!\S$["&WXWX[<#.M8#:8>W7T%!@98*G@^\QS\2 M>&>"@::M9):1ZY9HUBVDP#MW-&,*W9*3LY1OZ-TO>F\D0\V+IX[-83(TG!)B MH2=XIUNC^.1'0C$(*.NE)+11%[LE/ULX[+W?#M.6]@W5SXKJEE(C)E\$VZ<_ M-[:++%LZ]+;#=DR[&=M[#QU2#I#UY9F$:"!:=4[1K-38MX<1K'?EO_^DRML1 MECWO,FX14J\9XH!KEL4Y9Z ![B5]3';S.?*)7;R89\^.>@/B!52IE\E//U6$ MKRTO27%YFOQX9S($LD/U0AG]'U1B5_$12@,P%ML$(S_0LK >X-N9*IZW"-]= M[G1#O&>-R\0M],RRVF$7MYRIH9LB<(=>>-^.2$0EN:/!B)&_.#F\>T,7:Q[""2"AXAONE^YZ--,) X/T^Y*;SD4^*J6ZO4D5\UN>A/6YM=[6<8[)\=V-V9:-( M#G&Z3\_LUE9"#?W K$1X4AMW^ZWC6NAE"RL:6W419-8J>K&SBJEV<\^;9,G4 MFFNDM"$AG%3[;&HU;*5G"W8J[@/!SO/*I]5_ $M'@*"5P.1+^_L#@!T+(!@ MV(7"A 8CQ0P5""S.(N!+&+@)%^R-8Q20Z2N88.?W'+K&R0F!/RB1[(XKJ =@ MIJ&'NU[4\_"@,A+CZQA\*GUE\P?^NKBD>$BG<4D:I#DRE?BZ0&6;*\5;7!G^ M@>\FV^14G*(Z.%B-0S9<@B%^E7) >@PF&AR0X)Y.5,;>5SDX'TQ]%8C0A*S^ M4C%_SI+11./TGDC>,/!PXF^_5\T/%C=\/EZW+YKM;./Z\K)^TVE6DP_?\X:/ MZZ[<\2'F(\#';%]L.-S0TFR(AP8<]^PXYQ26#W:D&WNM/9F'?&L[R@L&7J$> M2>->7W )&D)(A8JF ;Q2,);VZ(I49Z09Q/HC37J&N7C!0VVV>*!DN1Y:"A8J M"N034I<2M0U2JU7D.?*8'9V3?:C[.JI+4*LVB4O#$-2IQ_PCLNYM*U87-&;G ML]'Y*O,68:MG*Q5 M#NVN'=07QM9/3VHQ12)T/H'+%F,T+SQJO!TR:V@ 2RBQ4'?\P \A4 )<" \A@.E\ G\%&Z\ M$Q,ADE'(-7@[U"[DHGM4.'%L?*CVB?!VYW?R&7M9AW$4TMR@5K%W>FQ$NW_V M;AYF+T9(8"8.6AB)QU?6J4G(/P^\#TPTUX\ M.BTYJZ=#+H MQ" E+L>*J!OF=NSQ(O:* 0(+:M3[-RQ('!N%4E@H%N#I6;/^[!HL)C#$EA4# M=DR5'@LA3-,I_Q4ZF!VC_ >L:%!I3)GW!*E4HF!1[R$3.+19W&7IH M84@G=F6B)>:HK+7!CS!A;N+23U5/+"*4$*R%H5K2ORG=6MXQF_?FW)U5KY>5E(!_\$R<<+8[^CY)KN3)?%ZVZ%:EE">7(6&@KR:TO ,T*] M K(LO-B]O&63LG("7"?G[HJ3!XS8.27V=91^V2T5W9+/QJ[CY@9ZB$LM\:^: ML\!IYF#UF+YG;,ZQ,@8H%;<:)]-/>TCQ>WW .-!UB;R?>S9+SSB9#0'?DAL8 M'FGA"J(VKK^@FA)S6?N0@>KQ_=C'C9WBEE%V!%\;3/SX?4_O4VOMP3-E]M5! M&\U VIH?I#=982'_'^ZSONK5VD[K\U6]^WN[V7GVW9WT"]YL_@0"9#G;(-PB MIW:T*O'BCX()\>@(DR4FO69?98;=]"# @=%" 81F&&WVV( &?'[2".65WF\Y>G##$P,2YH=&WM M6E%S&CD2?J>*_Z CERVG"F-PG,3!F"H,Q*;6:[LPF[WGA:^>5B,.I7V.WHPV7_M!+( M4.S/A)S.3/-*Q7,>5-JL7,+\K@B-B-NMWN!]-OA.^F;6/*Z]DF&%\4!.0RP@ M)J9BQ=QDP^8\GLIPWZBH68_,"4N?Q\H8-7>O)BHT^UK^1S0;^?.$SV6P;([D M7&AV)>[84,TY)'4N!^=7IY68E*RT6V?M_N>9'$O#R&+6.CAKMPYNV@4%"JL? M8O4-?>ZI4VG_$(YU=$*K6--'G;/+/NOV+R]O;SK=P=7Y::5>L<\WG5XO>_YE MT!M=G%8:]?KS"CN['O;Z0_L^5<*]V0?JEYV;VWXS^^518S>161GO66]4K'Z, M5!RVTU]ZF2*O&L^!SL&HEW]YG\YVMN8J9P/7%S@ZSM[CQ[ @*C,IXE.Q/XX% M_[0O0RU]T>0+)7WV92:U-Y2#7YQ=>#WXZ9S=#KNGE>EQX^AEXX@D-GCM8S0E M)$:GE]<_0TK4V]F/KT_C@1N!-5CXL?\4AZ]%?@):M@\F^ MUI$G[+YN-[&:*R-5N"+//)ZS:(;*VV+K]2Y"JR=XS'X$X,U'HG@GDKHJG,;< M) $G3*0GXAK[ MH!)V)X. Q2)2L:')W1GW(6V,8*DR-['_67B)D0N1360R%1M"LU@%HL9&,ZE9 M( Q(G6EAH%EBK")X,C@^R=6]DV;&.CZ/2%Z5W^N72,G/I&&,XBAEG8ZX%TSS@\9(<\?>7 MQ_5JO5YG$7RU1.A6X3BM&8^B0'I\#-XP_#.MQA0\&%N?S%3@RW"J:X_Q]*[@ M/1.AF$BC5] ^9?*NUI5A(BAO M += !RDM? K0QT9Z,N+&+D"9L."Q5(EF,\$#!+E=1003'HML:18%G-).AEZ0 M$-SETC16291-04XF,;?*8?*">S8 *?E!"L@RKI%[ =)#^':$")&<@?"_C=-4 MF'P;C[U3LQ-0WHZ*3@:##"(SK2)Z^ M36B_0]$Q53S03&B#9)9ZAK7&2UK!RK$K81Q60>87E? _)MJ0_AK??4&32/DB MV='#7(+E1T;%:?P9LMH&JYV] BJ7]$W"L?]K(LV2=>YX['^;L!R$ M%"\A5:>LD*T521NN*S=+K2FN.&)#FUC:G-5&>9]8$H()]H:W/[]@2&L$#;S[ MLE$]?%UG>@:V $$0]GS-Y<6I-VM3W[PBLB^7W-P:>1#%7?A.0W+1T)LK) M=CKAT4ZE5*"^0:2J4L[09&B$R<;GD M"^H]K'RJ@/Z69BEO)FAJR@W (5W/2E_ /TPM4 >UFT MB$V E)63X^N"#T1'#5[F'IV,/P+(K/D<"NI/8?_(1L0M&4P-!# <"I/$(=N+ M1[?#%]M=2H',M:4WS$OC%/Q4Y#,9^N(S31]+9020B@01D9T,1U!G<[_YU (+ M4I21Y988&)_":@*M]L.SX\;;5R=/O@U]GWJ,W,"!7NH!Z@(**&Y4'RWB!1KO M8K$IM&OE4A8&-@%JK(-UA4O7[Y1+X-854D/%?*"6L+V9POR79'3-SDE1DS5A(X MM?*HO= KY13EFG"D7+GD\03\2-'C+VQ>HV]%;-3R^20$#8#*&M@TF I5/.+> M)]M%Q,3@:'>T',L N .(QZ2S!X4_N5-0TO\U%#ZG0OGOW]AS[4:BW=(J5(@X MW=A28TX!^C$)-VH\.C]P:\RN5&AQ-C:$J_2L%;)4&NY>W,0*(X6AK1C% _;S M$^E38H$G!Z'E:KLT?>R)A0A4Y$I")\LIMN3Q+NH3-O?%82XB7]B% M;K&0VS=T\LPT"ETS;>]@$=C#)$;8-"-EP!:K'$:\HJ2)<-5 9G%6+L5BBI3, M\O,A0EFNIY,K()BP!".!J%&9A65"!V$HI@@I=[Q1I7,)!"CUO.D+"KU,,_V@ M:C5&>P0/.U[0D>N[B %IB$M?\%(2^EF'NRH3KG@]BNMJE[U&$1E5ZW0KN)5K M,RRVN".MUK%:2)WA9@I'*CG2VTY/"HJD!+/:1*@P6)*9G/G*2](AU,_A-;'N M^MY@D_N[_>M5:A_T!N_;K8/T&L4>I=,Y8.2.&M?S3\SOI1^]*IQ%C@5B731Y M<,>7F@X,#R(25.!-N3,?;;9^N[L9)JR6%F4_2 F'M26%',\>:] MU3<\1>53H@2U<:AIZ1WO"Z>1PM((=MUV/X'DGO&%K:_Y49 KMAB6'IR52XG^ M&[:]PA["V3X'B68W.\4$3W?+&I49NEHB\"DW40#N2! *=JCN N%G]9Q[GHB, M99&4N HLMEKWWE;[*VXZ;$*M7S.Q+[US3SNHT#3WLY=?E$"WM!N(1;"LKE^VK$-2 M6+)@VD5_<'XQ M"OURU[:)6_%+#Y:9G;UX8J4%/JRKLJCE2<7CA\!>1KL;W5 M%8>_ARO^(/"?+9LK=!^]C'_H&OX/8L>!/F#OJ,5$(;A4WW-TI^#V4+N;Q:O' M(]=E?8=YIS"WSMK%$-Z\U_\+(^-NY6^$0B.:7I;XW W\^F-$,K,7P9C=PK^!M/[#$Q.O>![RT?W+^ M7U!+ 0(4 Q0 ( *"+B5@/N_Q-00, &$+ 1 " 0 M !A9'!T+3(P,C0P-# T+GAS9%!+ 0(4 Q0 ( *"+B5AN\8\D8 8 +Y# M 5 " 7 # !A9'!T+3(P,C0P-# T7VQA8BYX;6Q02P$" M% ,4 " "@BXE8!R&>LKP$ "**@ %0 @ $#"@ 861P M="TR,#(T,#0P-%]P&UL4$L! A0#% @ H(N)6 9O'A2#$ *V< M X ( !\@X &0X,30S,31D.&LN:'1M4$L! A0#% @ MH(N)6,#I!9>["@ >2X !$ ( !H1\ &0X,30S,31D97@Q <,#$N:'1M4$L%!@ % 4 0 $ (LJ $! end XML 20 d814314d8k_htm.xml IDEA: XBRL DOCUMENT 0001478320 2024-04-04 2024-04-04 Adaptive Biotechnologies Corp false 0001478320 8-K 2024-04-04 WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 (206) 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false